Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
10.95
+2.42 (28.37%)
At close: Oct 17, 2025, 4:00 PM EDT
9.05
-1.90 (-17.35%)
Pre-market: Oct 20, 2025, 5:13 AM EDT
Addex Therapeutics Revenue
Addex Therapeutics had revenue of 36.38K CHF in the quarter ending June 30, 2025, a decrease of -68.45%. This brings the company's revenue in the last twelve months to 167.29K, down -79.93% year-over-year. In the year 2024, Addex Therapeutics had annual revenue of 410.04K, down -74.64%.
Revenue (ttm)
167.29K CHF
Revenue Growth
-79.93%
P/S Ratio
40.45
Revenue / Employee
83,643 CHF
Employees
2
Market Cap
8.51M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ADXN News
- 18 days ago - Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 24 days ago - Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 - GlobeNewsWire
- 27 days ago - Addex Appoints Bank of New York Mellon as Depositary Bank - GlobeNewsWire
- 4 months ago - Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs - GlobeNewsWire
- 4 months ago - Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders - GlobeNewsWire
- 4 months ago - Addex Shareholders Approve All Resolutions at Annual General Meeting - GlobeNewsWire
- 4 months ago - Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update - GlobeNewsWire